,
Risk assessment, prognosis and guideline implementation in pulmonary arterial hypertension, Eur Respir J, vol.50, 2017. ,
URL : https://hal.archives-ouvertes.fr/hal-01757586
Vascular stiffness mechanoactivates YAP/TAZ-dependent glutaminolysis to drive pulmonary hypertension, J Clin Invest, vol.126, pp.3313-3335, 2016. ,
URL : https://hal.archives-ouvertes.fr/hal-02479282
New targets for pulmonary arterial hypertension: going beyond the currently targeted three pathways, Curr Opin Pulm Med, vol.23, pp.377-385, 2017. ,
Role of Stromelysin 2 (Matrix Metalloproteinase 10) as a Novel Mediator of Vascular Remodeling Underlying Pulmonary Hypertension Associated With Systemic Sclerosis, Arthritis Rheumatol, vol.69, pp.2209-2221, 2017. ,
New molecular targets of pulmonary vascular remodeling in pulmonary arterial hypertension: importance of endothelial communication, Chest, vol.147, pp.529-537, 2015. ,
Chronic hypoxic pulmonary hypertension in rats and increased elastolytic activity, Am J Physiol, vol.261, pp.1716-1726, 1991. ,
Complete reversal of fatal pulmonary hypertension in rats by a serine elastase inhibitor, Nature medicine, vol.6, pp.698-702, 2000. ,
Overexpression of the serine elastase inhibitor elafin protects transgenic mice from hypoxic pulmonary hypertension, Circulation, vol.105, pp.516-521, 2002. ,
, , 1989.
, SC-39026, a serine elastase inhibitor, prevents muscularization of peripheral arteries, suggesting a mechanism of monocrotaline-induced pulmonary hypertension in rats, Circulation research, vol.64, pp.814-825
Inhibition of matrix metalloproteinases by lung TIMP-1, 2003. ,
, gene transfer limits monocrotaline-induced pulmonary vascular remodeling in rats, Human gene therapy, vol.14, pp.861-869
Pirfenidone for idiopathic pulmonary fibrosis: analysis of pooled data from three multinational phase 3 trials, Eur Respir J, vol.47, pp.243-253, 2016. ,
, Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials, vol.377, pp.1760-1769, 2011.
URL : https://hal.archives-ouvertes.fr/hal-00873255
A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis, N Engl J Med, vol.370, pp.2083-2092, 2014. ,
, , 2011.
, Antifibrotic activities of pirfenidone in animal models, Eur Respir Rev, vol.20, pp.85-97
Dasatinib induces lung vascular toxicity and predisposes to pulmonary hypertension, J Clin Invest, vol.126, pp.3207-3218, 2016. ,
URL : https://hal.archives-ouvertes.fr/inserm-02579754
Ectopic upregulation of membrane-bound IL6R drives vascular remodeling in pulmonary arterial hypertension, J Clin Invest, vol.128, pp.1956-1970, 2018. ,
URL : https://hal.archives-ouvertes.fr/inserm-02580448
A critical role for p130Cas in the progression of pulmonary hypertension in humans and rodents, Am J Respir Crit Care Med, vol.186, pp.666-676, 2012. ,
URL : https://hal.archives-ouvertes.fr/inserm-00905191
Leptin signalling system as a target for pulmonary arterial hypertension therapy, Eur Respir J, vol.45, pp.1066-1080, 2015. ,
URL : https://hal.archives-ouvertes.fr/inserm-02579431
Autocrine fibroblast growth factor-2 signaling contributes to altered endothelial phenotype in pulmonary hypertension, Am J Respir Cell Mol Biol, vol.45, pp.311-322, 2011. ,
URL : https://hal.archives-ouvertes.fr/inserm-00579959
Pro-proliferative and inflammatory signaling converge on FoxO1 transcription factor in pulmonary hypertension, Nat Med, vol.20, pp.1289-1300, 2014. ,
FoxO1 mediates TGF-beta1-dependent cardiac myofibroblast differentiation, Biochim Biophys Acta, vol.1863, pp.128-138, 2016. ,
TGF-beta1/Smad3 Pathway Targets PP2A-AMPK-FoxO1 Signaling to Regulate Hepatic Gluconeogenesis, J Biol Chem, vol.292, pp.3420-3432, 2017. ,
FoxO3 an important player in fibrogenesis and therapeutic target for idiopathic pulmonary fibrosis, EMBO Mol Med, vol.10, pp.276-293, 2018. ,
Right ventricular fibrosis and dysfunction: Actual concepts and common misconceptions, Matrix Biol, pp.507-521, 2018. ,
Limiting collagen turnover via collagenase-resistance attenuates right ventricular dysfunction and fibrosis in pulmonary arterial hypertension, 2016. ,
Pirfenidone attenuates cardiac fibrosis in a mouse model of TAC-induced left ventricular remodeling by suppressing NLRP3 inflammasome formation, Cardiology, vol.126, pp.1-11, 2013. ,
Pirfenidone prevents the development of a vulnerable substrate for atrial fibrillation in a canine model of heart failure, Circulation, vol.114, pp.1703-1712, 2006. ,
, , 2010.
, Pirfenidone mitigates left ventricular fibrosis and dysfunction after myocardial infarction and reduces arrhythmias, Heart Rhythm, vol.7, pp.1438-1445
,
Attenuation of cardiac fibrosis by pirfenidone and amiloride in DOCA-salt hypertensive rats, Br J Pharmacol, vol.135, pp.961-968, 2002. ,
The transcription factor Foxc1 is necessary for Ihh-Gli2-regulated endochondral ossification, Nat Commun, vol.6, p.6653, 2015. ,
,
,
Optimising experimental research in respiratory diseases: an ERS statement, Eur Respir J, p.51, 2018. ,
URL : https://hal.archives-ouvertes.fr/hal-01996906
,
Updated clinical classification of pulmonary hypertension, J Am Coll Cardiol, vol.62, pp.34-41, 2013. ,
Nintedanib in Severe Pulmonary Arterial Hypertension, Am J Respir Crit Care Med, 2018. ,